GlassScriptPhysician profile
Reza Ghorbani
NPI 1033194584
$24,432.27
in general payments reported to CMS, 2019-2025
23 companies · $1,912 in 2025
The $1,912 reported for 2025 was more than what 81% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,089 · 2020: $2,308 · 2021: $4,104 · 2022: $6,164 · 2023: $2,487 · 2024: $5,368 · 2025: $1,912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,948 · Travel and Lodging: $2,820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,947.52 |
| Travel and Lodging | $2,819.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $10,968.57 | 2019-2025 | Proclaim, Eterna, Octrode |
| Boston Scientific Corporation | $6,032.79 | 2020-2025 | Wavewriter Alpha Prime 16, Infinion 16, Infinion 16 |
| Medtronic, INC. | $1,952.61 | 2021-2022 | |
| Spinal Simplicity, LLC | $1,923.83 | 2024-2025 | Ha Minuteman G3-R, Liberty Si |
| Medtronic USA, INC. | $969.81 | 2019-2020 | |
| Nevro Corp. | $855.75 | 2020-2022 | |
| Collegium Pharmaceutical, INC. | $386.60 | 2024-2025 | Xtampza, Belbuca |
| Si-Bone, INC. | $338.36 | 2021-2022 | |
| Spinefrontier, INC. | $222.92 | 2024 | Inspan |
| Vertos Medical, INC. | $167.90 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.17 | 2019-2024 | Relistor |
| Intrinsic Therapeutics | $137.24 | 2023 | Barricaid Acd (Annular Closure Device) |
| Bioventus LLC | $83.33 | 2025 | Stimrouter Implantable Kit |
| Pfizer INC. | $45.68 | 2019 | |
| Painteq LLC | $26.88 | 2024 | Painteq |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $24.86 | 2021 | |
| Orexo US, INC. | $24.70 | 2019 | |
| Depuy Synthes Sales INC. | $23.81 | 2019 | |
| Medline Industries LP | $23.51 | 2024 | |
| Fidia Pharma USA INC. | $22.84 | 2020 | |
| Spr Therapeutics, INC | $21.45 | 2021 | |
| Grt US Holding, INC. | $18.76 | 2021 | |
| Vertical Pharmaceuticals, LLC | $15.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reza Ghorbani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.